Iovance Biotherapeutics, Inc.
A biotechnology company focused on the development and commercialization of novel cancer immunotherapies.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Iovance's stock with a target price of $25.75, indicating strong growth potential.
Financial Health
Iovance Biotherapeutics is earning revenue and cash flow, but its profit margins are low.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring IOVA
Alternative Cancer Therapies Focus Shifts 2025
The FDA's new boxed warning for Johnson & Johnson and Legend Biotech's cancer drug highlights potential safety issues in CAR-T therapies. This could shift focus to companies developing alternative and potentially safer oncology treatments.
Published: October 13, 2025
Explore BasketWhy You’ll Want to Watch This Stock
TIL Immunotherapy Focus
Develops tumour‑infiltrating lymphocyte therapies, a personalised approach for solid tumours; manufacturing and regulatory hurdles remain, so outcomes can vary.
Clinical Catalysts Ahead
Upcoming trial readouts and regulatory decisions could materially move the share price; these are binary events and can drive volatility.
Commercial Opportunity & Risk
If approved, therapies address sizeable oncology markets but require complex manufacturing, payer engagement and scalability — execution risk is significant.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals develops treatments for diseases including cystic fibrosis and cancer.
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals is a leading biotechnology company that develops and manufactures innovative medicines for serious medical conditions.
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing therapeutics based on RNA interference (RNAi).
